Treatment News : Sustiva Raises Suicide Risk, But Absolute Risk Is Still Low

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » November 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

November 1, 2013

Sustiva Raises Suicide Risk, But Absolute Risk Is Still Low

The HIV antiretroviral Sustiva (efavirenz) doubles the rate of suicidality—suicidal thoughts and behaviors—among those starting therapy for the first time, although the overall risk remains minimal, aidsmap reports. Researchers examined four AIDS Clinical Trials Group studies of 5,332 treatment-naive people with HIV who were enrolled between 2001 and 2007. They compared the risk of suicidal thoughts or attempts, both successful and unsuccessful, between 3,241 participants randomized to take regimens containing Sustiva and 2,091 randomized to take Sustiva-free regimens. The investigators presented their findings as the IDWeek conference in San Francisco.

During a median follow-up period of 150 weeks, 47 people in the Sustiva group experienced suicidality, for a rate of 8.08 per 1,000 person years, compared with 15 people in the Sustiva-free group, for a rate of 3.66 per person years. Consequently, Sustiva was found to increase the risk of suicidality by a factor of 2.28. There were 17 attempted or completed suicides in the Sustiva group, for a rate of 2.90 per 1,000 person years, compared with 5 in the Sustiva-free group, for a rate of 1.22 per 1,000 person years.

The investigators concluded that clinicians should carefully monitor for suicidality in those taking regimens including Sustiva. Sustiva is a component of the single-pill combination therapy Atripla (efavirenz/tenofovir/emtricitabine).

To read the aidsmap story, click here.

Search: HIV, antiretrovirals, Sustiva, efavirenz, suicidality, suicidal thoughts, suicide attempts, AIDS Clinical Trials Group, IDWeek, Atripla, tenofovir, emtricitabine.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    Newhopenate
    New Hope
    Pennsylvania


    sefarady
    New York
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.